Novo Nordisk has announced plans to move its ziltivekimab into phase 3 clinical development in atherosclerosis with chronic kidney disease after a mid-stage trial met its main goal.

New York, USA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Novo Nordisk’s OZEMPIC Approval Heat Up the Chronic Kidney Disease Therapeutic Market | DelveInsight The FDA’s recent approval of OZEMPIC ...

After its potential kidney disease drug went down in flames late last year, Novo Nordisk is pinning the ... systolic blood pressure in a phase 3 chronic kidney disease trial.

In this regard Novo Nordisk is leading the way. We've become increasingly committed to chronic conditions that include cardiovascular disease and chronic kidney disease – the reason being ...

Still, Novo is steadfast in its goal to eventually become a leader in the space, the company’s EVP of rare disease, Ludovic ...

With semaglutide shortages in the rearview, Novo Nordisk is doubling down on marketing efforts for its GLP-1 drugs.

NovoCare Pharmacy will provide all dose strengths of Wegovy at a reduced cost of $499 per month for cash-paying patients ...

Martin Holst Lange, Executive Vice President, Development, Novo Nordisk, highlighted during the press briefing that their ...

Novo Nordisk responded ... adults with T2D and established CV disease, and to reduce the sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease, and CV death in adults ...

Novo Nordisk launched "My Ozempic® Era" today, a national campaign which spotlights the longstanding Ozempic® patient ...

Novo Nordisk's blockbuster medication has gained another label expansion, now authorized for treating chronic kidney disease. New York, USA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Novo Nordisk's ...

New York, USA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Novo Nordisk’s OZEMPIC Approval Heat Up the Chronic Kidney Disease Therapeutic Market | DelveInsight The FDA’s recent approval of OZEMPIC highlights ...